Phase I/II Study of LBL-024 in Advanced Malignant Tumors Initiated by Nanjing Leads Biolabs
Nanjing Leads Biolabs has initiated Phase I/II clinical trial for LBL-024 targeting advanced malignant tumors.
Asset / Drug
Drug and asset intelligence for LBL-024 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.